Pipeline Programs
CGT Companies Tracked
Manufacturing Facilities
The global cell therapy human raw materials market size was estimated at US$ 4.35 billion in 2025 and is projected to grow to US$ 22.75 billion by 2034, rising at a compound annual growth rate (CAGR) of 22.38% from 2023 to 2034.
Cell therapy has become a very exciting area of study with novel therapeutic possibilities for a variety of illnesses. Although human cells are essential components for producing products for cell therapy, they frequently bring about a great deal of variability. On the other hand, the optimal collection of high-quality, consistent cellular material is made possible by strict operational controls and quality systems. The functioning of raw materials employed in cell therapy must enable desirable cellular activity. This covers the survival, differentiation, and multiplication of cells. It is crucial to choose raw materials that are suitable for the targeted therapeutic applications and the particular cell types.
The immense potential of artificial intelligence in healthcare is demonstrated by the industry's rapid expansion and large investments in R&D. The industrial industry is expected to face a financial effect of $3.8 trillion by 2035, while the AI market is predicted to reach an astounding $407 billion by 2027. The healthcare sector has been the most heavily invested in, with an estimated $6.1 billion in 2022. Over the past ten years, artificial intelligence (AI) and machine learning (ML) predictive techniques have transformed various biological domains, such as genome annotation, protein structure prediction, and synthetic enzyme design. By applying these predictive techniques to the creation of cell treatments, it may be possible to create better cell therapies more quickly and with fewer resources.
For instance,
Cell therapy human raw materials are biological and specialized ingredients used in the development and manufacturing of cell-based therapies, including culture media, growth factors, cytokines, supplements, and other essential components. The market is expanding due to the growing development of cell-based treatments and increasing investments in advanced therapeutic research. Current trends include demand for GMP-grade, xeno-free, serum-free, and chemically defined materials to improve safety and manufacturing consistency.
Technological advancements in gene editing, automated cell processing, cryopreservation, and closed-system manufacturing are creating demand for more specialized raw materials. Key drivers include increasing clinical trials, expansion of biopharmaceutical manufacturing, and growing interest in personalized medicines. Future opportunities are emerging in CAR-T therapies, stem cell treatment, NK-cell therapies, and iPSC-based applications, supporting demand for reliable, scalable, and high-quality raw material solutions.
Personalized Medicine Drives the Market
The cell therapy human raw materials market is growing due to the growing demand for personalized medicines due to various genetic, autoimmune, and chronic conditions along with cancer. These diseases require personalized medicines for better quality of care and better health outcomes. During cell therapy, the genetic material of an individual is used along with environmental conditions and lifestyle to develop better cell therapies, which will require human raw materials from individuals for testing and other purposes.
Market Restraint: Risk of Contamination and Variability
One of the biggest obstacles is the inherent danger of contamination and unpredictability in human raw ingredients. Striving for repeatability in cell treatments requires maintaining consistency in cell quality and features. Therefore, possible obstacles such as contamination and variability exist.
Opportunity: Expansion of Cell Sources
Further investigation into other cell sources, such as hematopoietic stem cells (HSCs), induced pluripotent stem cells (iPSCs), and mesenchymal stem cells (MSCs), among others, offers a chance to grow the industry. Cell treatments may be made more versatile and applicable by investigating and adding novel cell types.
There are currently close to 400 million rare illness patients globally as the frequency of these conditions rises yearly. Certain malignancies and uncommon disorders may be treated or even cured with cell and gene therapy (CGT). There may soon be a surge of novel gene treatments available. Over the next five years, it is anticipated that the CGT will almost triple. The numerous qualities of cell/gene therapy make it a wise option for treating uncommon ailments. Once mastered, replacing or repairing damaged genes is a highly reproducible strategy that may be used to treat a wide range of genetic illnesses.
For instance,
By Product Insights
Why Did the Cell Culture Supplements Segment Dominate in the Market?
By product, the cell culture supplements segment held the largest share of the cell therapy human raw materials market in 2025. With the use of cell culture supplements, labs can modify and enhance media formulations to meet the needs of certain cell culture applications, including the creation of proteins, hybridomas, Chinese hamster ovary (CHO) cells, various serum-free processes, and more. The supplements evaluated in cell culture and insect culture that are gathered here have been applied and tested to ensure that they work well in cell culture systems. Many culture parameters, including the right medium composition for your cell line, are critical to ensuring proper cell development. Basal or complex media can be improved and supplemented with lipids, vitamins, amino acids, serum, and antibiotics to assist cell development.
For instance,
The Cell Culture Media Segment: Fastest-Growing
By product, the cell culture media segment is anticipated to grow at the fastest rate in the cell therapy human raw materials market during the forecast period. For the purpose of supplying the elements required to sustain cell growth and function, cell culture media is essential. The nutrients and growth factors your culture environment needs for the cells to behave as predicted are provided by components in the cell culture medium. Furthermore, media may be designed to control pH and osmotic pressure, two other environmental factors in cell growth. Different formulations of cell culture medium have been created to accommodate a broad range of cell types and experimental uses.
For instance,
By End-Use Insights
What Made Biopharmaceutical & Pharmaceutical Companies the Dominant Segment in the Market?
By end-use, the biopharmaceutical & pharmaceutical companies segment dominated the cell therapy human raw materials market in 2025. Cell and gene therapy is being used by pharmaceutical corporations to treat complicated medical diseases and expand treatment alternatives. Pharmaceutical corporations are strategically investing in cell and gene therapy in addition to concentrating on innovation to expand their patent portfolios. The goal of these expenditures is to put oneself at the forefront of industry innovations and close profitable partnerships with partners. A few of the most recent agreements highlight the significance of gene and cell therapy for the pharmaceutical sector.
The CROs & CMOs Segment is the Fastest Growing
By end-use, the CROs & CMOs segment is expected to showcase the fastest CAGR in the cell therapy human raw materials market during the predicted period. Biotechnology and pharmaceutical businesses frequently turn to third-party suppliers for development and manufacturing help, most frequently to CROs, CMOs, or CDMOs, in order to manage industry challenges and fill resource shortfalls. Both bio/pharma businesses and CDMOs continue to invest in the development and manufacturing capabilities for cell and gene treatments, which represent a niche but expanding industry on a product basis. Due to the industry's limited capacity for these novel modalities, CDMOs of all sizes continue to make investments in research and development as well as production capacity.
By region, North America dominated the cell therapy human raw materials market share by 45.80% in 2025. The region's dominance may be attributed to supportive government policies, an increasing need for innovative treatments, and coordinated efforts by significant industry players to improve cell therapy products that treat a range of chronic illnesses. Furthermore, North America is home to a large number of well-known businesses that produce and sell cell-based goods, which is driving up demand for human raw materials for cell therapy and further expanding the market. Moreover, joint ventures between major industry participants and smaller biotechnology enterprises intensify rivalry as firms endeavor to strengthen their positions in the constantly changing cell therapy sector.
For instance,
U.S. Market Trends
The presence of well-developed R&D infrastructures in the U.S. is increasing the demand for cell therapy raw materials due to growing innovations in CAR-T, personalized, and stem cell therapies. The stringent regulations and growth in healthcare investments are also increasing their demand.
Canada: Emerging Hub for Cell Therapy Raw Materials
Canada’s cell therapy raw materials market is growing due to increasing investment in biotechnology, expanding cell and gene therapy research, and strengthening biomanufacturing infrastructure. Government initiatives and collaboration between research institutions and industry are supporting innovation in advanced therapies. Rising demand for high-quality standardized and GMP-grade raw materials, along with growing clinical development activities, is further creating opportunities for market expansion.
By region, Asia Pacific is expected to grow at the fastest rate during the forecast period. The rise in demand for advanced cell treatments and the heightened emphasis on biotechnology are the reasons for this surge. The market is growing because of the establishment of manufacturing facilities, strategic partnerships, and increased R&D activity by major industry players. Additionally, the Asia-Pacific region's highest market share belonged to China's Cell Therapy Human Raw Materials market, while India's Cell Therapy Human Raw Materials market grew at the quickest rate.
| CAR-T Cell Therapies Approved in Asia | |||
| Brand | Manufacturer | Country | Year of Approval |
| Carvykti | Legend Biotech, J&J | Japan & South Korea | 2023 |
| Yuanruida (CNCT19) | JUVENTAS | China | 2023 |
| Carteyva | JW Therapeutics | China | 2021 |
| Fucaso | IASO BIO, Innovent | China | 2023 |
| Saikaize (Zevor-cel) | Carsgen Therapeutics | China | 2024 |
| Abecma | BMS, bluebird bio | Japan | 2022 |
| Breyanzi | BMS | Japan | 2021 |
| Yescarta | Kite Pharma, Fosun Kite | Japan & China | 2021 |
| Kymriah | Novartis | Japan, South Korea and Taiwan | 2021 |
China Market Trends
The expanding industries in China are increasing the development of regenerative and cell & gene therapies, which is driving the demand for cell therapy raw materials. At the same time, the growing government initiatives, increasing disease burden, and expanding development of generic products are also increasing their use.
India Emerges as a growth engine for Cell Therapy Raw Materials
India is notably expanding in the cell therapy human raw materials market due to rising biotechnology research, increasing cell and gene therapy development, and growing healthcare innovation. The country’s expanding biopharmaceutical manufacturing base, skilled workforce, and cost-effective research capabilities are attracting greater investment. Growing clinical studies and demand for specialized culture media, growth factors, reagents, and other essential inputs are further supporting market development.
Europe is expected to grow significantly in the cell therapy raw materials market during the forecast period, due to a robust regulatory framework, which increases the use of high-quality raw materials for cell therapies. The growing gene therapy clinical pipeline is also increasing their demand, where the growing R&D activities and their increasing adoption rates are also enhancing the market growth.
UK Market Trends
The growing advancements in cell and gene therapies in the UK are increasing the demand for their raw materials. The growing adoption of cell therapies and regenerative medicines is also increasing their use, where the growing demand for personalized medicine and stringent regulations are also promoting their use.
Germany Strengthened Cell Therapy Raw Materials Growth
Germany is notably expanding in the cell therapy human raw materials market due to its advanced biotechnology sector, strong research capabilities, and increasing development of cell and gene therapies. Growing biopharmaceutical manufacturing activities are driving demand for specialized raw materials. The country’s skilled workforce, established scientific infrastructure, and increasing focus on innovative therapeutic solutions are further supporting market growth.
R&D
Clinical Trials and Regulatory Approvals
Formulation and Final Dosage Preparation
Patient Support and Services
| Company Name | REPROCELL |
| Headquarters | Kanagawa, Japan, Asia Pacific |
| Recent Development | In May 2024, REPROCELL generated human-induced pluripotent stem cells (hiPSCs) that were therapeutically relevant by managing the donor recruiting process for seed stock hiPSCs and ensuring donor eligibility with several regional regulatory bodies. Strict selection is applied to the raw materials, and a patented technique for footprint-free RNA reprogramming is employed. In order to produce hiPSC and hMSC that are appropriate for therapeutic application, REPROCELL has recently expanded this offering by purchasing a Cytocentric Xvivo system model 2 from BioSpherix, which is a closed GMP cell culturing system. |
| Company Name | Pluri Inc. |
| Headquarters | Haifa, Israel, Middle East |
| Recent Development | In January 2024, the biotech company Pluri Inc. introduced PluriCDMO, a new business division that provides contract development and manufacturing organization (CDMO) services for cell therapy production. From its cutting-edge, 47,000-square-foot GMP cell therapy production facility, PluriCDMO will provide development and manufacturing services to assist clients in overcoming significant obstacles in the creation and manufacture of cell-based medicines. |
By Product
By End-Use
By Region
Principal Consultant
Payal Rabde is a Healthcare Market Research Analyst at Towards Healthcare Research & Consulting with 4+ years of experience in pharmaceuticals, biotechnology, medical devices, and life sciences.
Learn more about Payal Rabde
Reviewed By
Aditi Shivarkar is a seasoned professional with over 14 years of experience in healthcare market research. As a content reviewer, Aditi ensures the quality and accuracy of all market insights and data presented by the research team.
Learn more about Aditi Shivarkar
